Enrichment of LDL with EPA and DHA decreased oxidized LDL-induced apoptosis in U937 cells.
Oxidized LDL (oxLDL) may contribute to the accumulation of apoptotic cells in atherosclerotic plaques. Although it is well established in monophasic chemical systems that the highly unsaturated EPA and DHA will oxidize more readily than FA that contain fewer double bonds, our previous studies showed that enrichment of LDL, which has discrete polar and nonpolar phases, with these FA did not increase oxidation. The objective of this study was to compare the extent of apoptosis induced by EPA/DHA-rich oxLDL to that induced by EPA/DHA-non-rich oxLDL in U937 cells. LDL was obtained from one healthy subject three times before and after supplementation for 5 wk with 15 g/d of fish oil (FO), an amount easily obtainable from a diet that contains fatty fish. After supplementation, an EPA/DHA-rich LDL was obtained. Oxidative susceptibility of LDL, as determined by measuring the formation of conjugated dienes and the accumulation of cholesteryl ester hydroperoxides, was not higher in EPA/DHA-rich LDL. The oxLDL-induced cell apoptosis was detected by the activation of caspase-3, the translocation of PS to the outer surface of the plasma membrane using the Annexin V-fluorescein isothiocyanate binding assay, and the presence of chromatin condensation and nuclear fragmentation using the 4,6-diamidino-2-phenylindole staining assay. All three measures showed that after FO supplementation, EPA/DHA-rich oxLDL-induced cell apoptosis decreased. The decrease was not related to the concentration of lipid hydroperoxides. This study suggests that a possible protective effect of EPA/DHA-rich diets on atherosclerosis may be through lessening cell apoptosis in the arterial wall.
Wu
Tianying
T
Human Nutrition Research Laboratory, University of North Carolina at Greensboro, 27402-6170, USA.
Geigerman
Cissy
C
Lee
Ye-Sun
YS
Wander
Rosemary C
RC
D000328:Adult; D000475:Alkenes / Q000378:metabolism; D017209:Apoptosis / Q000187:drug effects*; D053148:Caspase 3; D020169:Caspases / Q000378:metabolism; D004281:Docosahexaenoic Acids / Q000494:pharmacology*; D004347:Drug Interactions; D015118:Eicosapentaenoic Acid / Q000494:pharmacology*; D005227:Fatty Acids / Q000032:analysis; D005395:Fish Oils / Q000008:administration & dosage; D006801:Humans; D015227:Lipid Peroxidation / Q000187:drug effects; D008077:Lipoproteins, LDL / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology*; D008297:Male; D013194:Staining and Labeling / Q000379:methods; D013997:Time Factors; D020298:U937 Cells; D014810:Vitamin E / Q000378:metabolism
D000475:Alkenes; D005227:Fatty Acids; D005395:Fish Oils; D008077:Lipoproteins, LDL; C099252:oxidized low density lipoprotein; D014810:Vitamin E; D004281:Docosahexaenoic Acids; D015118:Eicosapentaenoic Acid; C505407:CASP3 protein, human; D053148:Caspase 3; D020169:Caspases